Variant Pharmaceuticals Licenses Worldwide Rights From L&F Research


WESTON, Fla., Dec. 18, 2015  — Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant’s lead product, VAR 200.  VAR 200 has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney, including focal segmental glomerulosclerosis (FSGS), a rare disease affecting up to 133,000 people in the United States.  FSGS is a leading cause of chronic kidney failure, and there are currently no targeted drug treatments nor cure.

“VAR 200, if successfully developed and commercialized, will redefine the treatment of FSGS,” says Pablo Guzman, MD, FACC, and acting Chief Medical Officer at Variant. “We believe that VAR 200 has potential to minimize or prevent kidney cell damage and improve FSGS prognosis.”

Subscribe to get the latest news